# Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

> **NCT03961204** · PHASE4 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 662 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **OTHER:** Data Collection

## Key facts

- **NCT ID:** NCT03961204
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-15
- **Primary completion:** 2021-02-27
- **Final completion:** 2021-05-13
- **Target enrollment:** 662 (ACTUAL)
- **Last updated:** 2023-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961204, "Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03961204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*